Maintenance Olaparib Prolongs PFS in BRCA-Mutated Pancreatic Cancer

The prognosis of patients with metastatic pancreatic cancer (mPCA) remains poor, despite use of modern chemotherapy regimens such as FOLFIRINOX and nab-paclitaxel/gemcitabine. After progression on frontline therapy, less than half of the patients are eligible for second-line treatment. There is a high, unmet need for targeted biomarker selected treatment approaches. In ovarian and breast cancer, […]

Read More

Enzalutamide Improves Survival in Hormone-Sensitive Prostate Cancer

The treatment of metastatic hormone-sensitive prostate cancer (HSPC) has undergone a major evolution in recent years. While androgen deprivation therapy (ADT) remains the backbone of care, several studies have demonstrated an improvement in long-term survival when the cytotoxic agent docetaxel or the androgen biosynthesis inhibitor abiraterone are added to ADT. Enzalutamide is a potent direct […]

Read More

Pembrolizumab ± Chemotherapy, a New First-Line Standard for HNSCC

For the past decade, the standard first-line treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been the combination of cetuximab, platinum chemotherapy, and 5-FU followed by cetuximab maintenance, commonly referred to as the “EXTREME regimen.” However, while this regimen results in a 10.1-month overall survival (OS), it is associated […]

Read More

Breast cancer

Adjuvant T-DM1 New Standard in Early HER2-Positive Breast Cancer

The standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer has evolved significantly in recent years as new agents and combinations have emerged that improve upon standard adjuvant and neoadjuvant treatment with trastuzumab alone. Patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant chemotherapy […]

Read More

Multiple myeloma cells

Daratumumab-Rd Regimen New Standard for Transplant Ineligible Myeloma

  The majority of patients with newly diagnosed multiple myeloma are treated with a triplet of bortezomib, lenalidomide, and dexamethasone (VRd) induction therapy, followed by transplant and maintenance therapy. However, some patients, in particular the elderly, are ineligible for transplant due to frailty or comorbidities. For these patients, treatment with regimens such as VRd or […]

Read More

gut microbiome, melanoma, PD-1

Gut Microbiota Before Bone Marrow Transplantation Predicts Survival

Allogeneic hematopoietic cell transplantation (allo-HCT) is an important treatment for many hematologic malignancies. While this therapy can be life saving for some patients with hematologic cancers, it can be associated with a  complications, including infection, organ toxicity, and graft-versus-host disease (GVHD). The composition of the intestinal microbiota is a known factor influencing toxicity and outcomes […]

Read More

New Data on CAR T-Cell Therapy in Hematologic Malignancies

Chimeric antigen receptor modified (CAR) T cells have emerged in recent years as a novel and highly effective treatment option for patients with different hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). At the 2018 American Society for Hematology (ASH) Annual Meeting, new findings from several […]

Read More

Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS

Anemia is a major morbidity associated with low- and intermediate-risk myelodysplastic syndrome (MDS), and patients with MDS often become dependent on red blood cell (RBC) transfusion to counteract symptoms of anemia. Luspatercept, a first-in-class erythroid-maturation agent, is involved in regulation of late stage RBC maturation and is currently being investigated as a treatment for patients […]

Read More

Ibrutinib Regimens Outperform Chemoimmunotherapy in Newly Diagnosed CLL

From December 1 to December 4, more than 25,000 attendees from around the world gathered in San Diego, California, to attend the 60th American Society for Hematology (ASH) Annual Meeting, where the latest developments and new findings in the hematology field were presented. Over the next several weeks, prIME Lines will highlight some of the […]

Read More

First-Line Avelumab Plus Axitinib Outperforms Sunitinib in RCC

For many years, the standard front-line therapy for advanced renal cell carcinoma (RCC) with clear cell histology was single-agent treatment with a vascular endothelial growth factor (VEGF) targeting tyrosine kinase inhibitor (TKI). Recently, however; immunotherapy with the PD-1 inhibitor nivolumab in combination with the CTLA-4 inhibitor ipilimumab was approved for use in patients with intermediate- […]

Read More